Growth Hormone and Brain Functioning After Traumatic Brain Injury
| Status: | Completed |
|---|---|
| Conditions: | Hospital, Neurology |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 9/12/2018 |
| Start Date: | December 1, 2009 |
| End Date: | April 1, 2014 |
Growth Hormone and Brain Functioning After Traumatic Brain Functioning
The current protocol aims to compare the brain-functioning (fMRI & EEG) and white matter
structural integrity (DTI) of persons with mild to severe TBI with and without Growth Hormone
deficiency during cognitive tasks; and to examine changes in cognitive and motor performance,
EEG/fMRI and white matter integrity associated with growth hormone treatment for twelve
months using an open-label design in persons with GH deficiency/insufficiency following mild
to severe TBI. To meet this aim, we are in the process of screening 40 persons with mild to
severe TBI, ages 18-55, who are at least six months post injury. After screening, 10 persons
with TBI and GHD (Growth Hormone deficiency) will receive daily rhGH injections titrated to
bring their GH levels into the normal range over the course of twelve months. Treatment will
be initiated using rhGH (Genotropin). Subjects with TBI and GHD will be assessed at baseline,
6 months, and 12 months with EEG, fMRI and DTI, and neuropsychological measures. 5 persons
with TBI who do not have GHD will be assessed at baseline and at 12 months with EEG, fMRI and
DTI, and neuropsychological measures.
structural integrity (DTI) of persons with mild to severe TBI with and without Growth Hormone
deficiency during cognitive tasks; and to examine changes in cognitive and motor performance,
EEG/fMRI and white matter integrity associated with growth hormone treatment for twelve
months using an open-label design in persons with GH deficiency/insufficiency following mild
to severe TBI. To meet this aim, we are in the process of screening 40 persons with mild to
severe TBI, ages 18-55, who are at least six months post injury. After screening, 10 persons
with TBI and GHD (Growth Hormone deficiency) will receive daily rhGH injections titrated to
bring their GH levels into the normal range over the course of twelve months. Treatment will
be initiated using rhGH (Genotropin). Subjects with TBI and GHD will be assessed at baseline,
6 months, and 12 months with EEG, fMRI and DTI, and neuropsychological measures. 5 persons
with TBI who do not have GHD will be assessed at baseline and at 12 months with EEG, fMRI and
DTI, and neuropsychological measures.
Inclusion Criteria:
- Mild to Severe TBI
- At Least 6 Months Post Injury
- Ages 18-55
Exclusion Criteria:
- Patients Taking Anticoagulants, Anticonvulsants, Cyclosporine, Corticosteroids, and
Sex Steroids
- History of Hepatitis B or C
- History of Symptomatic Coronary Disease or Congestive Heart Failure
- Pre-Existing Neurologic Disease such as Epilepsy, Alzheimer's Disease, Multiple
Sclerosis, Brain Tumors, etc.
- Obesity (BMI > 30)
- Pregnant or Lactating Females
- Penetrating Traumatic Brain Injury
- Having a Pacemaker
- Diabetes and Diabetic Retinopathy
- Serious Psychiatric Conditions (e.g., Schizophrenia, Bipolar Disorder, Major
Depressive Disorder, etc.)
- Patients with Language Problems such as Aphasia
- Any Sign of Neoplastic Activity
- Active Malignancies
- Three-Fold Elevation of Liver Function Tests (ALP, ALT, AST)
- Partially Deficient in Both Cortisol and Thyroid
- Fully Deficient in Either Cortisol and Thyroid
- Patients with Claustrophobia
- Metal in the Body that Cannot be Removed (especially in the head)
- Amputations on Upper Body Limbs
We found this trial at
1
site
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
